Blog

Future Targets for Acute Myeloid Leukemia (AML)


VIEW THE PRESENTATION

Speaker:
E. Anders Kolb,
MD
Associate Professor
Vice Chairman for Research
Department of Pediatrics
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
Director, Nemours Center for Cancer and Blood Disorders Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE

The laboratory and clinical work theme of E. Anders Kolb has been efficient and effective translation of novel therapies into children. A founding member of the National Cancer Institute-funded Pediatric Preclinical Testing Program, Dr. Kolb is an end-user of banked, well-annotated clinical specimens and recognizes their inherent critical value to translational medicine. He has successfully completed preclinical evaluations of numerous anti-cancer strategies in human tissues and aided in the translation of these agents into clinical trials. Exploring the mechanism of action of targeted compounds, Dr. Kolb developed an expertise in genomics, proteomics and cell signaling to support diverse results-driven research and laboratory methodologies. Within the Children’s Oncology Group, Dr. Kolb serves as Chair, Myeloid Disease Committee; Member, Scientific Council; Member, Young Investigator Mentoring Committee; and Member, Bone Tumor Committee. Through this, he has expertise and experience in collaborative science, resource stewardship, clinical research development, clinical trial design and implementation, and in the necessities of young investigator development. He has helped to design, implement and ensure adequate accrual onto pediatric treatment and banking studies. Progress and survival in pediatric diseases has reached a plateau. The ability of individual labs and programs to impact major improvements in care is diminishing. Progress through collaborative science is the clear path forward

Comments are closed.